甲氨蝶呤移植物抗宿主病预防后亚叶酸钙解救的疗效:双盲随机对照研究结果
多中心双盲随机对照试验纳入52例接受清髓性预处理外周血干细胞移植、环孢素联合甲氨蝶呤预防GVHD的患者,随机接受亚叶酸钙或安慰剂。预设中期分析显示3-4级口腔黏膜炎发生率两组相似(46.6% vs 45.8%;P = .97),未支持研究继续;结论为亚叶酸钙解救不降低方案相关毒性,也不影响移植结局。
要点
- 亚叶酸钙组与安慰剂组3-4级口腔黏膜炎发生率相似:46.6% vs 45.8%(P = .97)。
- 1-4级口腔黏膜炎发生率两组相似:83.3% vs 77.8%(P = .65)。
- 中位随访17个月,急慢性GVHD、复发、非复发死亡及总生存均无差异。
核心结论
- 甲氨蝶呤GVHD预防后亚叶酸钙解救不降低方案相关毒性,也不影响移植结局。
- 预设中期分析结果未支持研究继续。
研究设计与样本
- 多中心、双盲、随机、对照试验,纳入接受清髓性预处理外周血干细胞移植、环孢素联合甲氨蝶呤预防GVHD的患者。
- 患者随机接受亚叶酸钙或安慰剂,自每次甲氨蝶呤给药后24小时开始,持续24小时,分3至4次给药。
- 入组52例患者(亚叶酸钙组n = 28;安慰剂组n = 24),主要终点为3级和4级口腔黏膜炎发生率。
主要发现
- 3级和4级口腔黏膜炎发生率亚叶酸钙组46.6% vs 安慰剂组45.8%(P = .97)。
- 1至4级口腔黏膜炎发生率亚叶酸钙组83.3% vs 安慰剂组77.8%(P = .65)。
- 中位随访17个月(范围4.5-50个月),急性和慢性GVHD、疾病复发、非复发死亡及总生存率均无差异。
局限性
- 预设中期分析后未支持研究继续,结果基于52例患者的中期数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis is associated with increased rates of organ-specific toxicities. Despite limited data, the European Society for Blood and Marrow Transplantation-European LeukemiaNet working group recommend the use of folinic acid (FA) rescue to reduce MTX toxicity after allogeneic hematopoietic cell transplantation (allo-HCT). In a multicenter, double-blind, randomized, controlled trial, we explored whether FA rescue reduces MTX-induced toxicity. We enrolled patients undergoing allo-HCT with myeloablative conditioning with peripheral blood stem cell grafts, with GVHD prophylaxis consisting of cyclosporine and MTX. Patients were randomized to receive FA or placebo starting 24 hours after each MTX dose and continuing over 24 hours in 3 to 4 divided doses. The primary end point was the rate of grades 3 and 4 oral mucositis. After enrollment of 52 patients (FA, n = 28; placebo, n = 24), preplanned interim analysis revealed similar rates of grade 3 and 4 (46.6% vs 45.8%; P = .97) and grades 1 to 4 (83.3% vs 77.8%; P = .65) oral mucositis. With a median follow-up of 17 (range, 4.5-50) months, there was no difference in the rates of acute and chronic GVHD, disease relapse, nonrelapse mortality, and overall survival. These interim results did not support continuation of the study. We conclude that FA rescue after MTX GVHD prophylaxis does not decrease regimen-related toxicity or affect transplantation outcomes. This study was registered at clinicaltrials.gov as #NCT02506231.
引用
- Yeshurun M, Rozovski U, Pasvolsky O, et al. Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. Blood Adv. 2020. PMID: 32790844. doi:10.1182/bloodadvances.2020002039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。